An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will report its first quarter 2024 financial results on May 2, 2024. The company focuses on developing small molecule medicines through targeted protein degradation. Investors can access the conference call via phone or live webcast on the company's website.
Kymera Therapeutics, una società biofarmaceutica in fase clinica, comunicherà i risultati finanziari del primo trimestre del 2024 il 2 maggio 2024. L'azienda si concentra sullo sviluppo di medicinali a piccole molecole tramite la degradazione proteica mirata. Gli investitori possono partecipare alla teleconferenza tramite telefono o attraverso la trasmissione web dal vivo disponibile sul sito web della società.
Kymera Therapeutics, una compañía biofarmacéutica en fase clínica, informará los resultados financieros del primer trimestre de 2024 el 2 de mayo de 2024. La empresa se enfoca en el desarrollo de medicinas de moléculas pequeñas mediante la degradación dirigida de proteínas. Los inversores pueden acceder a la llamada de conferencia por teléfono o mediante la transmisión en vivo en el sitio web de la compañía.
임상 단계의 바이오제약 회사인 Kymera Therapeutics가 2024년 1분기 재무 결과를 2024년 5월 2일에 발표할 예정입니다. 이 회사는 표적 단백질 분해를 통해 소분자 의약품을 개발하는 데 중점을 두고 있습니다. 투자자들은 회사 웹사이트에서 전화 또는 실시간 웹캐스트를 통해 컨퍼런스 콜에 접속할 수 있습니다.
Kymera Therapeutics, une entreprise biopharmaceutique en phase clinique, publiera ses résultats financiers pour le premier trimestre 2024 le 2 mai 2024. La société se concentre sur le développement de médicaments à petites molécules par la dégradation ciblée des protéines. Les investisseurs peuvent accéder à la conférence téléphonique par téléphone ou via une webdiffusion en direct sur le site Web de l'entreprise.
Kymera Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, wird am 2. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 veröffentlichen. Das Unternehmen konzentriert sich auf die Entwicklung von kleinen Molekül-Medikamenten durch gezielten Proteinabbau. Investoren können die Telefonkonferenz über das Telefon oder per Live-Webcast auf der Website des Unternehmens verfolgen.
Positive
None.
Negative
None.
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET.
To access the May 2 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s conference call will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.
When will Kymera Therapeutics report its first quarter 2024 financial results?
Kymera Therapeutics will report its first quarter 2024 financial results on May 2, 2024.
What is Kymera Therapeutics' ticker symbol?
Kymera Therapeutics' ticker symbol is KYMR.
How can investors access the conference call for Kymera Therapeutics?
Investors can access the conference call for Kymera Therapeutics by dialing +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and asking to join the call. They can also watch a live webcast on the company's website.
What is Kymera Therapeutics' focus in drug development?
Kymera Therapeutics focuses on developing small molecule medicines using targeted protein degradation (TPD).
kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.
